Best of the Brokers for 25 February 2015

To appear in Best of the Brokers, email your research to

FinnCap reiterated its “sell” rating on the healthcare company, following news that the FDA has approved VenaSeal, a surgical glue used to treat varicose veins, from rival firm Covidien. The broker noted that Covidien has “an established sales force much larger than that to which BTG could aspire”.

Cantor Fitzgerald reiterated its “buy” rating on the gas company. The firm plans to grow its reserves base through an active drilling programme and a focus on connecting wells to existing infrastructure, and the broker said it believes these actions will help the firm achieve its targets for 2015.

Numis reiterated its “buy” recommendation on the media group, ahead of its 2014 results. A recent update from the firm confirmed that profits and EPS will be marginally ahead of expectations, and the broker stated that shares remain good value. Target price is 249p.